Venclexta already has a fairly broad label in the relapsed/refractory CLL population ... in patients receiving it for multiple myeloma in a trial’s control arm – causing AbbVie and Roche ...
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...
EMA grants PRIME designation to Nurix Therapeutics’ NX-5948 to treat relapsed or refractory chronic lymphocytic leukaemia: San Francisco Friday, November 22, 2024, 16:00 Hrs [IS ...